• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性心肌梗死中链激酶大剂量、短疗程静脉输注:对循环系统影响的描述

High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.

作者信息

Mentzer R L, Budzynski A Z, Sherry S

出版信息

Am J Cardiol. 1986 Jun 1;57(15):1220-6. doi: 10.1016/0002-9149(86)90192-x.

DOI:10.1016/0002-9149(86)90192-x
PMID:3717017
Abstract

The effects in the circulating blood of a 1-hour intravenous infusion of 1.5 X 10(6) units of streptokinase (SK) were measured during the subsequent 24-hour period in 7 patients with acute myocardial infarction. At the end of the infusion, the activator activity, expressed in SK units, averaged 65 U/ml, all of the plasminogen had disappeared, only a small amount of free plasmin was still present and functionally active alpha 2 antiplasmin had been reduced to 21% of the preinfusion level. All of the native fibrinogen had been degraded and the thrombin-coagulable protein was composed entirely of fragment X species, but the circulating plasma also contained significant amounts of the more extensively degraded fragments Y, D and E. The biologic half-life of the SK-induced activator activity was 23 minutes and that of the fibrinogen degradation products was 6.3 hours. The lytic effects persisted for 4 hours before any signs of recovery from the hemostatic defect were evident; considerable recovery was present at 25 hours.

摘要

在7例急性心肌梗死患者中,于随后24小时期间测定了静脉输注1.5×10⁶单位链激酶(SK)1小时后循环血液中的效应。输注结束时,以SK单位表示的激活剂活性平均为65 U/ml,所有纤溶酶原均消失,仅存在少量游离纤溶酶且功能活跃,α2抗纤溶酶已降至输注前水平的21%。所有天然纤维蛋白原均已降解,凝血酶可凝固蛋白完全由X片段组成,但循环血浆中也含有大量降解程度更高的Y、D和E片段。SK诱导的激活剂活性的生物半衰期为23分钟,纤维蛋白原降解产物的生物半衰期为6.3小时。溶栓效应持续4小时,之后才出现止血缺陷恢复的任何迹象;25小时时已有相当程度的恢复。

相似文献

1
High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.急性心肌梗死中链激酶大剂量、短疗程静脉输注:对循环系统影响的描述
Am J Cardiol. 1986 Jun 1;57(15):1220-6. doi: 10.1016/0002-9149(86)90192-x.
2
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.急性心肌梗死患者静脉输注重组人组织型纤溶酶原激活剂期间的凝血与纤溶分析
Circulation. 1986 Mar;73(3):511-7. doi: 10.1161/01.cir.73.3.511.
3
Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。
Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.
4
Activation of the fibrinolytic system during intracoronary streptokinase administration.冠状动脉内注射链激酶期间纤溶系统的激活。
J Am Coll Cardiol. 1987 Jan;9(1):189-96. doi: 10.1016/s0735-1097(87)80100-6.
5
Coagulation and fibrinolytic changes in evolving acute myocardial infarction treated by high-dose, brief-duration intracoronary or intravenous streptokinase.大剂量、短疗程冠状动脉内或静脉内注射链激酶治疗进展期急性心肌梗死时的凝血及纤溶变化
Am J Clin Pathol. 1990 Feb;93(2):246-51. doi: 10.1093/ajcp/93.2.246.
6
High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial.大剂量静脉注射链激酶治疗急性心肌梗死:一项多中心试验的初步结果
J Am Coll Cardiol. 1985 Nov;6(5):957-62. doi: 10.1016/s0735-1097(85)80294-1.
7
Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.冠状动脉内注射链激酶对急性心肌梗死和冠状动脉供血不足患者的纤溶作用。
Circulation. 1983 May;67(5):1031-8. doi: 10.1161/01.cir.67.5.1031.
8
Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.急性心肌梗死患者静脉注射茴香酰化纤溶酶原链激酶激活剂复合物或肝素后凝血与纤溶分析。一项比利时多中心研究。
Drugs. 1987;33 Suppl 3:253-60. doi: 10.2165/00003495-198700333-00047.
9
Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.链激酶和组织型纤溶酶原激活剂溶栓治疗期间片段X形成的定量分析。
J Clin Invest. 1987 Jun;79(6):1642-7. doi: 10.1172/JCI113001.
10
Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.链激酶可诱导急性心肌梗死患者血管内血小板激活因子的释放,并刺激培养的人内皮细胞合成该因子。
Circulation. 1993 Oct;88(4 Pt 1):1476-83. doi: 10.1161/01.cir.88.4.1476.

引用本文的文献

1
Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.急性心肌梗死的溶栓治疗。应吸取的教训。
Tex Heart Inst J. 1991;18(2):103-9.
2
The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.补体膜攻击复合物有助于纤溶酶诱导内皮细胞和中性粒细胞合成血小板活化因子。
Immunology. 2003 Aug;109(4):557-63. doi: 10.1046/j.1365-2567.2003.01692.x.
3
Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.
链激酶。老年患者急性心肌梗死中其药理学及治疗效果的综述
Drugs Aging. 1994 Jan;4(1):63-86. doi: 10.2165/00002512-199404010-00007.
4
Pharmacokinetic optimisation of the treatment of embolic disorders.栓塞性疾病治疗的药代动力学优化
Clin Pharmacokinet. 1995 Jan;28(1):67-92. doi: 10.2165/00003088-199528010-00006.
5
Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.茴香酰化纤溶酶原链激酶激活剂复合物及其他溶栓药物在动物和人体中的药代动力学特性。
Drugs. 1987;33 Suppl 3:88-92. doi: 10.2165/00003495-198700333-00013.
6
Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.静脉注射茴香酰化纤溶酶原链激酶激活剂复合物治疗急性心肌梗死的生物学研究
Drugs. 1987;33 Suppl 3:268-74. doi: 10.2165/00003495-198700333-00049.
7
The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma.酰化对人血浆中茴香酰化纤溶酶原链激酶激活剂复合物稳定性的保护作用。
Drugs. 1987;33 Suppl 3:57-63. doi: 10.2165/00003495-198700333-00007.
8
Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.链激酶和组织型纤溶酶原激活剂溶栓治疗期间片段X形成的定量分析。
J Clin Invest. 1987 Jun;79(6):1642-7. doi: 10.1172/JCI113001.
9
Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.静脉注射链激酶。对其在急性心肌梗死治疗中的应用重新评估。
Drugs. 1990 May;39(5):693-719. doi: 10.2165/00003495-199039050-00006.
10
A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.链激酶和茴香酰化纤溶酶原链激酶激活剂复合物在急性心肌梗死中的药代动力学特性比较。
Br J Clin Pharmacol. 1991 Feb;31(2):143-7. doi: 10.1111/j.1365-2125.1991.tb05502.x.